StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
12
Publishing Date
2024 - 03 - 04
14
2023 - 12 - 21
13
2023 - 12 - 12
13
2023 - 12 - 06
14
2023 - 11 - 27
13
2023 - 10 - 23
12
2023 - 10 - 18
13
2023 - 10 - 16
16
2023 - 10 - 04
14
2023 - 09 - 26
18
2023 - 09 - 20
12
2023 - 09 - 07
15
2023 - 08 - 23
12
2023 - 06 - 26
13
2023 - 06 - 15
12
2023 - 04 - 27
12
2023 - 04 - 25
15
2023 - 04 - 17
15
2023 - 03 - 27
12
2023 - 02 - 23
13
2023 - 01 - 30
16
2023 - 01 - 26
12
2023 - 01 - 25
15
2023 - 01 - 04
12
2022 - 11 - 17
13
2022 - 10 - 12
14
2022 - 10 - 06
14
2022 - 09 - 14
14
2022 - 09 - 13
12
2022 - 08 - 22
13
2022 - 05 - 24
12
2022 - 05 - 17
13
2022 - 05 - 03
14
2022 - 03 - 28
14
2022 - 01 - 24
18
2021 - 12 - 22
12
2021 - 12 - 13
15
2021 - 12 - 09
12
2021 - 12 - 06
13
2021 - 11 - 01
12
2021 - 10 - 18
15
2021 - 10 - 14
12
2021 - 10 - 12
12
2021 - 10 - 07
12
2021 - 10 - 04
12
2021 - 09 - 07
12
2021 - 06 - 29
12
2021 - 06 - 25
13
2021 - 06 - 23
14
2021 - 06 - 21
13
2021 - 06 - 11
11
2021 - 06 - 04
13
2021 - 06 - 03
12
2021 - 06 - 01
14
2021 - 05 - 21
15
2021 - 05 - 03
14
2021 - 04 - 14
11
2021 - 03 - 22
13
2021 - 01 - 04
11
2020 - 12 - 21
12
Sector
Finance
2
Health technology
9
Tags
Antibody
1
Approval
1
Berubicin
1
Biotech
1
Cancer
3
Clearance
1
Clinical-trials-phase-ii
1
Collaboration
1
Colorectal cancer
1
Cpi-613
2
Designation
3
Diagnostic
1
Disease
2
Drug
4
Dry eye
1
Enroll
2
Europe
1
Eye
1
Eye disease
1
Fast track
1
Fast track designation
1
Fda
5
Fda clearance
1
Fda-approvals
1
Gastrointestinal
1
Genetown
1
Glioblastoma
2
Grant
2
Granted
2
Iot
1
Lupus
1
Macular
1
Milestone
1
N/a
6
New drug
1
Nivolumab
1
Ocular
1
Pharm-country
1
Pharmaceutical
1
Phase 2
2
Phase 3
1
Positive
1
Potential
1
Research
1
Rosa
1
Satellite
1
Solid tumors
1
Test
1
Therapy
2
Train
1
Treatment
12
Trial
1
Entities
Anavex life sciences corp.
1
Brickell biotech, inc.
1
Bristol-myers squibb company
2
Clovis oncology, inc.
1
Cns pharmaceuticals, inc.
3
Cullinan management inc
1
Horizon therapeutics public limited company
1
Incyte corporation
1
Intellia therapeutics, inc.
1
Iterum therapeutics plc
1
Mannkind corporation
1
Ocular therapeutix, inc.
1
Onconova therapeutics, inc.
1
Palatin technologies, inc.
1
Pfizer, inc.
1
Rafael holdings, inc.
2
Reata pharmaceuticals, inc.
1
Regeneron pharmaceuticals, inc.
1
Symbols
AVXL
1
BBI
1
BMY
2
CGEM
1
CLVS
1
CNSP
3
HZNP
1
INCY
1
ITRM
1
MNKD
1
NTLA
1
OCUL
1
ONTX
1
PFE
1
PTN
1
REGN
1
RETA
1
RFL
2
Exchanges
Amex
1
Nasdaq
8
Nyse
5
Crawled Date
2021 - 06 - 29
12
Crawled Time
12:00
1
12:15
1
13:00
4
14:00
1
14:15
1
16:00
2
17:00
1
21:00
1
Source
www.biospace.com
6
www.globenewswire.com
2
www.prnewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
publishing date :
2021 - 06 - 29
save search
Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Published:
2021-06-29
(Crawled : 21:00)
- globenewswire.com
BBI
|
$2.12
16.04%
|
Health Technology
|
152.69%
|
O:
9.68%
H:
1.96%
C:
-6.74%
treatment
biotech
phase 3
iot
enroll
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer Company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers
Published:
2021-06-29
(Crawled : 17:00)
- biospace.com/
RFL
4
|
$1.78
-1.11%
0.0%
7.9K
|
Finance
|
-96.52%
|
O:
0.31%
H:
3.04%
C:
-2.82%
treatment
fda
potential
test
therapy
cancer
gastrointestinal
drug
cpi-613
milestone
designation
Global Graft Versus Host Disease (GVHD): Market Size from 2018 to 2030 and Overview of Treatment Practices and Emerging Drugs
Published:
2021-06-29
(Crawled : 16:00)
- prnewswire.com
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-37.83%
|
O:
-0.47%
H:
0.89%
C:
-0.6%
disease
treatment
drug
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer
Published:
2021-06-29
(Crawled : 16:00)
- globenewswire.com
RFL
4
|
$1.78
-1.11%
0.0%
7.9K
|
Finance
|
-96.52%
|
O:
0.31%
H:
3.04%
C:
-2.82%
treatment
fda
cancer
drug
cpi-613
granted
grant
designation
Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
Published:
2021-06-29
(Crawled : 14:15)
- biospace.com/
CGEM
|
$17.84
3.0%
2.91%
1.3M
|
|
-33.79%
|
O:
-0.42%
H:
4.09%
C:
-0.15%
new drug
fda clearance
treatment
fda
solid tumors
antibody
drug
clearance
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Published:
2021-06-29
(Crawled : 14:00)
- biospace.com/
HZNP
|
$116.3
0.03%
29M
|
Health Technology
|
21.34%
|
O:
-0.08%
H:
0.66%
C:
-0.95%
treatment
phase 2
trial
lupus
enroll
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Published:
2021-06-29
(Crawled : 13:00)
- prnewswire.com
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-27.32%
|
O:
0.0%
H:
0.32%
C:
-0.2%
REGN
|
$901.27
0.8%
0.78%
470K
|
Health Technology
|
64.76%
|
O:
-0.08%
H:
1.06%
C:
0.68%
NTLA
|
$21.52
-1.33%
-1.35%
1.1M
|
Health Technology
|
-83.65%
|
O:
-2.19%
H:
17.95%
C:
16.17%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-89.63%
|
O:
33.33%
H:
0.0%
C:
-20.52%
CLVS
|
$0.0812
-3.94%
|
Health Technology
|
-98.61%
|
O:
0.81%
H:
0.0%
C:
-5.95%
AVXL
|
$4.065
-1.34%
-1.35%
1.3M
|
Health Technology
|
-85.72%
|
O:
-0.59%
H:
0.17%
C:
-17.64%
treatment
glioblastoma
Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027
Published:
2021-06-29
(Crawled : 13:00)
- prnewswire.com
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-34.33%
|
O:
0.03%
H:
0.4%
C:
-0.08%
ONTX
|
$0.9953
-5.61%
1.3M
|
Health Technology
|
-86.52%
|
O:
-0.81%
H:
0.82%
C:
-4.62%
MNKD
|
$4.105
1.36%
1.34%
2.3M
|
Health Technology
|
-23.44%
|
O:
-1.13%
H:
2.1%
C:
0.0%
ITRM
|
$1.42
-2.07%
-2.11%
75K
|
Health Technology
|
-38.82%
|
O:
2.95%
H:
1.43%
C:
-2.05%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-89.63%
|
O:
33.33%
H:
0.0%
C:
-20.52%
treatment
diagnostic
train
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration
Published:
2021-06-29
(Crawled : 13:00)
- biospace.com/
OCUL
|
$7.58
-2.7%
-2.77%
980K
|
Health Technology
|
-44.56%
|
O:
1.07%
H:
0.99%
C:
-3.1%
treatment
ocular
collaboration
macular
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Published:
2021-06-29
(Crawled : 13:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
13.93%
|
O:
0.5%
H:
0.89%
C:
-3.47%
CNSP
A
|
$0.2064
-1.01%
-1.02%
210K
|
Health Technology
|
-89.63%
|
O:
33.33%
H:
0.0%
C:
-20.52%
berubicin
treatment
fda
fast track
fast track designation
granted
grant
designation
glioblastoma
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
Published:
2021-06-29
(Crawled : 12:15)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-27.32%
|
O:
0.0%
H:
0.32%
C:
-0.2%
satellite
treatment
rosa
europe
therapy
cancer
colorectal cancer
approval
nivolumab
Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease
Published:
2021-06-29
(Crawled : 12:00)
- prnewswire.com
PTN
|
$1.9
1.6%
-2.11%
230K
|
Health Technology
|
240.19%
|
O:
7.22%
H:
15.17%
C:
15.17%
dry eye
disease
treatment
fda
phase 2
eye
positive
eye disease
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.